Dec 01, 2022 / 02:00PM GMT
Edward Andrew Tenthoff - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
Good morning, everyone. My name is Ted Tenthoff. I'm a senior biotech analyst at Piper Sandler. And before I begin, firstly, thank you all for joining us.
And before I begin, I am required to point out certain disclosures regarding the relationship between Piper and Moderna that are posted at the back of the room and also at the registration desk.
So I don't think Moderna needs much of an introduction these days. I remember when we first did the IPO, it took a little bit more, but now pretty much a household name, thanks to all of your hard work in protecting us against the COVID pandemic.
But what I really love about the story, I think it's just getting excited now, because you have a dramatically strengthened balance sheet and really a fundamentally derisked technology and are developing a pipeline of new mRNA vaccines and medicines that I think are even going to have a bigger impact.
I'm very pleased to have my good friend, Stephane Bancel. Thanks for taking the
Moderna Inc at Piper Sandler Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers